Brokerages Set Roche Holding AG (OTCMKTS:RHHBY) PT at $51.50

Shares of Roche Holding AG (OTCMKTS:RHHBY) have earned a consensus rating of “Hold” from the eleven ratings firms that are covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $51.50.

A number of research analysts have weighed in on RHHBY shares. Morgan Stanley raised shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 price objective for the company in a report on Friday, April 24th. Wolfe Research reissued an “outperform” rating on shares of Roche in a research note on Thursday, February 26th. Finally, Argus raised shares of Roche from a “hold” rating to a “buy” rating in a research note on Monday, April 6th.

Roche Trading Up 0.6%

RHHBY opened at $51.65 on Wednesday. Roche has a fifty-two week low of $37.51 and a fifty-two week high of $60.85. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72. The company has a fifty day moving average of $51.06 and a two-hundred day moving average of $52.42.

Institutional Trading of Roche

Institutional investors and hedge funds have recently modified their holdings of the stock. Meritage Portfolio Management purchased a new stake in shares of Roche during the fourth quarter worth about $4,372,000. Hantz Financial Services Inc. increased its stake in shares of Roche by 164.9% during the fourth quarter. Hantz Financial Services Inc. now owns 79,732 shares of the company’s stock worth $4,112,000 after purchasing an additional 49,633 shares in the last quarter. Vestmark Advisory Solutions Inc. purchased a new stake in shares of Roche during the third quarter worth about $597,000. Verity Asset Management Inc. increased its stake in shares of Roche by 26.4% during the fourth quarter. Verity Asset Management Inc. now owns 13,886 shares of the company’s stock worth $716,000 after purchasing an additional 2,896 shares in the last quarter. Finally, Oakworth Capital Inc. increased its stake in shares of Roche by 20.8% during the fourth quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock worth $86,000 after purchasing an additional 285 shares in the last quarter.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.